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Objectives: A multicenter randomized phase II study was conducted to evaluate
the effects of Hochu-ekki-to (TJ-41) for reducing adverse reactions and increasing
compliance with S-1 adjuvant therapy for advanced gastric cancer.
Methods: The eligibility criteria were pathological stage II/III after R0 resection. Patients
received adjuvant therapy with S-1 alone (group S) or S-1 with TJ-41 (group ST) for 1 year.
The primary endpoint was the completion rate of S-1. Secondary endpoints were adverse
events, relative dose intensity, relapse-free survival (RFS), and overall survival (OS).
Results: We randomly assigned 56 patients to group ST and 57 patients to group S.
The completion rates of S-1 were 54.5 and 50.9%, the median relative dose intensities
were 89.2 and 71.9%, and adverse events of grade 3 or 4 occurred in 45.5 and 54.5%
in groups ST and S, respectively. There was no significant difference in 3-year OS or RFS
between the two groups.
Conclusions: TJ-41 does not increase relative dose and completion rate of S-1
significantly. J-41 may reduce toxic effects, but our findings do not support routine use
of TJ-41 after gastrectomy.
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INTRODUCTION
The standard treatment for advanced gastric cancer is surgical
resection with D2 lymphadenectomy followed by adjuvant
chemotherapy in Eastern countries, where gastric cancer is
common, while perioperative chemotherapy or chemoradiation
is preferred in Western countries (1–3). Adjuvant chemotherapy
with S-1 for 1 year yields a 5-year survival rate of 72%,
reducing the risk of death by 33% compared to surgery alone
(4). However, compliance with adjuvant chemotherapy following
radical gastrectomy is unsatisfactory. The ACTS-GC trial found
that 35% of patients drop out during a 1-year course of S-1
administration (1). Completion rates of S-1 for 1 year in other
prospective studies were even lower, from 39 to 63% (5–7).
Furthermore, even for patients who took S-1 for 12 months, the
dose was decreased in 47% of cases. Adverse events are the most
common reason for discontinuation or dose reduction, including
anorexia, nausea, diarrhea, stomatitis, and hematological events.
Both early termination of treatment and a decrease of relative
dose intensity are closely related to lower survival; therefore,
increasing compliance by reduction of toxicity is likely to
improve survival of these patients (8).
Hochu-ekki-to (TJ-41, Chinese name: Bu-zhong-yi-qi-tang,
Korean name: Bojungikki-tang) is a traditional herbal medicine
that originated in China and is composed of 10 species
of medicinal plant. It has long been used for general
fatigue, weakness, and loss of appetite (9). Several reports
have shown biological effects of TJ-41 augmenting immune
responses, reducing surgical stress, and preventing side effects of
chemotherapy (9–11). TJ-41 is often prescribed to cancer patients
in Japan, and has beneficial effects on cancer-related fatigue and
quality of life in these patients (12). We conducted a multicenter
randomized phase II study to test our hypothesis that TJ-41 may
improve compliance with S-1 by reducing its adverse reactions,
and improve survival of patients with advanced gastric cancer.
PATIENTS AND METHODS
Eligibility Criteria
The eligibility criteria included histologically proven gastric
cancer of pathological stage II/III after R0 resection according
to the 14th Japanese classification of gastric carcinoma, except
for T3N0 (13); negative peritoneal washing cytology, without
liver metastasis; age 20–80 years old; S-1 started within 8
weeks after surgery; provision of written informed consent; and
adequate organ function (white blood cells (WBC) ≥3,000 to
≤12,000 /mm3, neutrophils ≥1,500 /mm3, hemoglobin ≥9 g/dL,
platelets ≥100,000 /mm3, total bilirubin ≤1.5 mg/dL, aspartate
aminotransferase (AST) ≤100 IU/L, alanine aminotransferase
(ALT) ≤ 100 IU/L, creatinine clearance calculated by the
Cockcroft-Gault formula ≥60 mL/min). Patients were excluded
if they had synchronous cancer; preoperative chemotherapy or
radiotherapy; severe comorbidities such as bowel obstruction,
uncontrolled diabetes, severe diarrhea, pulmonary fibrosis
or heart disease; a requirement for a H2 blocker, proton
pump inhibitor, warfarin, phenytoin, or flucytosine; or a
contraindication for S-1.
Study Design and Sample Size
The primary endpoint was the completion rate of adjuvant
chemotherapy with S-1 for 1 year. Secondary endpoints were
adverse events of adjuvant chemotherapy, relative dose intensity,
relapse free survival (RFS), and overall survival (OS). A total
sample size of 110 patients was determined to have 80% power
at a one-sided alpha of 0.2 for detecting 15% improvement of
the baseline completion rate of 65%. Relative dose intensity
was defined as the ratio of actual dose of S-1 administered to
the planned dose in 1 year. Patients were considered to have
completed adjuvant chemotherapy when they received S-1 for 1
year at a relative dose intensity of ≥70%.
Patients were randomly assigned to the S-1 plus TJ-41 (ST)
group or the S-1 alone (S) group with a centralized computer
system stratified by cancer stage (II or III), institutions, and type
of surgery (total gastrectomy or other type of resection) at an
outsourced data center. Patients were to be followed for 3 years.
OS was defined as the time between the date of registration and
the date of death. RFS was defined as the time between the date
of registration and the date of relapse or death, whichever came
first. Relapse was determined by clinical signs or imaging such
as computed tomography (CT), endoscopy, or gastrointestinal
radiography. Evaluations by CT and based on CEA and CA19-
9 levels were performed at least every 6 months for the first 3
years. Data for event-free patients were censored on the date
the patient was last seen. The protocol was first approved by
the ethics review committee of Kyoto University on January
2011, and then approved by all participating centers. The original
accrual period was planned to be 2 years, with an additional
3 years of follow-up, but was extended by 5 months due to
delayed accrual. This trial is registered at the UMIN Clinical
Trials Registry (UMIN000004701).
Adjuvant Chemotherapy and Adverse
Events
Adjuvant chemotherapy was initiated within 8 weeks after
surgery. In group S, patients received oral S-1 at 80 mg/m2/day
for 4 weeks, followed by a 2-week recovery period. Patients with
body surface areas <1.25 m2, 1.25 to <1.5 m2, and ≥1.5 m2
received 80, 100, and 120mg of S-1 daily, respectively. This 6-
week cycle was repeated for 1 year after surgery. In group ST, 7.5
g/day of TJ-41 was additionally administered every day during
the same period.
Adverse events were assessed using the Common Toxicity
Criteria for Adverse Events (CTCAE, version 4.0). S-1 was
interrupted during the course when patients had hematologic
toxicity of grade 3, or, 4, or non-hematologic toxicity of
grade 2 or above, including appetite loss, nausea, vomit,
stomatitis, diarrhea, impaired hearing, and neurological or
cardiac disorders. Initiation of the next course was postponed
until recovery and fulfillment of the following criteria: WBC
≥2,000 /mm3, neutrophils ≥1,000 /mm3, platelets ≥75,000
/mm3, total bilirubin ≤3 mg/dL, AST/ALT ≤150 IU/L, and
creatinine clearance ≥30 mL/min. The daily dose of S-1 was
reduced from 120mg to 100mg, 100mg to 80mg, and 80mg to
50mgwhen the following adverse events occurred in the previous
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course: leukocytopenia or neutropenia of grade 4, other toxic
effect of grade 3 or 4, and creatinine clearance <60 ml/min.
When the association of adverse events and S-1 was unclear, or
adverse events occurred only after 14 days of S-1 administration,
modification to a 3-week cycle (S-1 on days 1-14 of each cycle
followed by a 1-week recovery period) was allowed, instead of
dose reduction. When adverse events of grade 3 or above that
were associated with TJ-41 occurred, TJ-41 was discontinued.
The protocol treatment was discontinued when patients
withdrew the consent, recurrences were diagnosed, severe
adverse events preventing treatment occurred, general condition
deteriorated severely, comorbidities deteriorated severely,
intended protocol violation was noticed, or according to
physicians’ discretion.
Statistical Analysis
For patient characteristics and efficacy endpoints, continuous
variables were compared by Wilcoxon rank sum test and
categorical variables were compared by chi-squared test. The
frequency of adverse events between treatment groups was tested
using Fisher’s exact test. Time-to-event endpoints were analyzed
by the Kaplan-Meier method and compared using a stratified log-
rank test with clinical stage and type of surgery as stratification
factors. Cox proportional hazards model was used to estimate
hazard ratios and their 95% confidence intervals. To examine if
TJ-41 had a beneficial effect on completion of adjuvant therapy,
subgroup analyses of completion rates in both groups were
analyzed based on age, sex, pathological stage, and type of
surgery. To estimate of odds ratios and to test for treatment group
by each factor interaction, logistic regression analysis was used.
The significant level was one-sided 0.2 for the primary endpoint,
a value of 0.05 was considered to indicate statistical significance
in the other analyses. All the analyses were conducted with SAS
version 9.4, JMP 13 (SAS Institute, Cary, NC, USA) and SPSS
Statistics version 19.0 (IBM, Armonk, NY, USA).
RESULTS
Characteristics of the Patients
Between March 2011 and July 2013, 113 patients from 25
hospitals were enrolled and assigned to treatment with S-1 plus
TJ-41 (group ST, n = 56) or S-1 alone (group S, n = 57). After
randomization, three patients were found to be ineligible due to
pathological T3N0 (n = 2 in group S) and not receiving study
medication (n = 1 in group ST). Therefore, the main analyses
were based on data from 110 eligible patients (n = 55 in each
group, Figure 1). The baseline characteristics of the 110 patients
were similar in the two groups (Table 1).
Completion of Adjuvant Chemotherapy
Adjuvant chemotherapy with S-1 for 1 year was completed by 30
patients (54.5%, 95%CI: 41.4–67.7%) in group ST and 28 (50.9%,
95%CI: 37.7–64.1%) in group S, with no significant difference in
the completion rate between the two groups (one-sided P= 0.35).
Cycle interruptions were needed in 24 (43.6%) and 34 (61.8%)
patients, the S-1 dose was reduced in 17 (30.9%) and 21 (38.2%)
patients, and cycle delay occurred in 13 (23.6%) and 14 (25.5%)
TABLE 1 | Background characteristics of the patients.
Characteristic S-1 plus TJ-41 S-1 only P*
(N = 55) (N = 55)
Sex 1.000
Male 37 (67.3) 37 (67.3)
Female 18 (32.7) 18 (32.7)
Age (median, range) 65, 49 to 76 64, 35 to 77 0.322
Neoadjuvant Chemotherapy 0.185
No 48 (87.3) 52 (94.5)
Yes 7 (12.7) 3 (5.5)
Type of Surgery 0.699
Distal/proximal gastrectomy 33 (60.0) 31 (58.4)
Total gastrectomy 22 (40.0) 24 (43.6)
T Category 0.088
T1 3 (5.5) 1 (1.8)
T2 9 (16.4) 16 (29.1)
T3 13 (23.6) 19 (34.5)
T4 30 (54.6) 19 (34.5)
N Category 0.281
N0 8 (14.5) 6 (10.9)
N1 13 (23.6) 19 (34.5)
N2 13 (23.6) 17 (30.9)
N3 21 (38.2) 13 (23.6)
Stage 0.561
II 21 (38.2) 24 (43.6)
III 34 (61.8) 31 (56.4)
Data are shown as number (%), except for age. *P-value for age calculated by Wilcoxon
rank sum test. P-values for other factors calculated by chi-squared test.
patients in groups ST and S, respectively. TJ-41 was discontinued
in two patients (3.6%). Reasons of discontinuation were bad
taste and appetite loss. No significant interaction between the
treatment groups and any of these variables was found in S-1
completion rate (Figure 3).
Relative Dose Intensity and Adverse Events
The median relative dose intensity of S-1 was 89.2% in group
ST and 71.9% in group S (P = 0.33). The difference was not
significant, but the percentage of patients who achieved a relative
dose intensity of 90% was marginally greater in group ST [26
(47.3%) vs. 17 (30.9%), P = 0.08]. Adverse events were the most
common reason for discontinuation of S-1 in both groups (ST
vs. S: 36 vs. 48%), followed by recurrence (36 vs. 30%), patients’
request (12 vs. 15%), and miscellaneous (16 vs. 7%). Reasons
and time points of discontinuation in each group were shown
in Table 2. During the treatment period, 25 patients (45.5%)
in group ST and 30 (54.5%) in group S had adverse events of
grade 3 or above (P = 0.446), with no significant difference
in the frequency and severity of adverse events between the
groups (Table 3).
Survival
The median follow-up period was 1,076 (range, 49–1751) days in
group ST and 1,084 (range, 207–1801) days in group S. The 3-
year OS rates were 63.9% (95% CI, 50.2–75.7) and 78.1% (95%
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CI, 65.3–87.1) (Figure 2A) and the 3-year RFS rates were 59.9%
(95% CI, 46.2–72.3) and 70.6% (95% CI, 56.2–81.8) (Figure 2B)
in groups ST and S. The hazard ratio for death and relapse
in the group ST compared with S was 1.68 (95% CI, 0.84–
3.48, P = 0.140), and 1.44 (95% CI, 0.75–2.81, RFS (P =
0.271), respectively.
DISCUSSION
The primary aim of this study was to evaluate if addition of
Hochu-ekki-to (TJ-41) increases compliance with S-1 after D2
gastrectomy for advanced gastric cancer. We found no statistical
TABLE 2 | Reasons and time points of discontinuation of S-1.
Reasons of
discontinuation of S-1
Time points of discontinuation of S-1
-3 months 4-6 months 7-12 months Total
S-1 PLUS TJ-41
Adverse events 8 0 1 9
Recurrences 0 2 7 9
Patients’ request 2 0 1 3
Miscellaneous 3 1 0 4
Total 13 3 9 25
S-1 ONLY
Adverse events 6 3 4 13
Recurrences 1 4 3 8
Patients’ request 1 0 3 4
Miscellaneous 2 0 0 2
Total 10 7 10 27
difference of 1-year completion rate of S-1 between the two
groups. Therefore, these results do not support routine use of
TJ-41 after gastrectomy for advanced gastric cancer.
However, there were marginal differences between the two
groups in relative dose intensity (89 vs. 72%) and rate of grade
3 or 4 adverse events (46 vs. 55%). Most of the adverse events
except for jaundice and skin rash were decreased with the use of
TJ-41. Although jaundice and skin rash in some patients might
be caused by TJ-41, there was no apparent severe side effects of
TJ-41. These findings suggest that TJ-41 does have some positive
effects in reducing toxicity, but the study was underpowered to
detect those effects. We calculated the sample size based on a
hypothesis that TJ-41 would increase the completion rate from
65 to 80%. In hindsight, this expectation was too high based
only on decreasing adverse effects of S-1, because 15% of patients
discontinued S-1 because of recurrence. This recurrence rate was
consistent with the ACTS-GC study based on a careful evaluation
of the RFS curves (1).
Although completion rate of S-1 was not different between
patients with or without TJ-41, subgroup analyses showed that
the completion rate for S-1 tends to be higher in elderly patients
(≥ 65 years) who received TJ-41 (Figure 3). TJ-41 is usually
prescribed for elderly patients with severe weakness, and several
functions including improvement of cancer-related fatigue,
increased oral food intake, and enhancement of immunological
responses were reported (12, 14). Therefore, optional use of TJ-41
may be reasonable in elderly patients after gastrectomy. However,
to clearly identify target patients who could benefit from TJ-41
following gastrectomy, further study is needed.
The overall and relapse-free survival was slightly better
in patients with S-1 only, while the completion rate of S-1
TABLE 3 | Adverse events in the two treatment groups at different CTCAE grades.
Adverse event S-1 plus TJ-41 S-1 only P-value*
(N = 55) (N = 55)
Grade ≥1 Grade ≥3 Grade ≥1 Grade ≥3 Grade ≥1 Grade ≥3
HEMATOLOGIC
Leukocytopenia 30 (54.5) 2 (3.6) 30 (60.0) 3 (5.5) 0.700 1.000
Neutrocytopenia 31 (56.4) 8 (14.5) 33 (60.0) 11 (20.0) 0.847 0.615
Anemia 48 (87.3) 5 (9.1) 50 (90.9) 0 (0) 0.761 0.057
Thrombocytopenia 22 (40.0) 1 (1.8) 23 (41.8) 2 (3.6) 1.000 1.000
Total bilirubin 34 (61.8) 0 (0) 28 (50.9) 1 (1.8) 0.336 1.000
Aspartate aminotransferase 18 (32.7) 2 (3.6) 21 (38.2) 1 (1.8) 0.690 1.000
Alanine aminotransferase 21 (38.2) 1 (1.8) 21 (38.2) 1 (1.8) 1.000 1.000
Creatinine 4 (7.3) 0 (0) 5 (9.1) 0 0 (0) 1.000 1.000
NON-HEMATOLOGIC
Nausea 26 (47.3) 1 (1.8) 28 (50.9) 1 (1.8) 0.849 1.000
Vomiting 8 (14.5) 1 (1.8) 16 (29.1) 1 (1.8) 0.105 1.000
Diarrhea 21 (38.2) 2 (3.6) 28 (50.9) 6 (10.9) 0.250 0.271
Appetite loss 33 (60.0) 2 (3.6) 36 (65.5) 4 (7.3) 0.694 0.679
Stomatitis 12 (21.8) 1 (1.8) 15 (27.3) 3 (5.5) 0.658 0.618
General malaise 25 (45.5) 1 (1.8) 27 (49.1) 4 (7.3) 0.849 0.363
Skin rash 17 (30.9) 1 (1.8) 10 (18.2) 1 (1.8) 0.183 1.000
Pigmentation 18 (32.7) NA 15 (27.3) NA 0.678 NA
Dysgeusia 11 (20.0) NA 13 (23.6) NA 0.818 NA
Total 54 (98.2) 25 (45.5) 55 (100) 30 (54.5) 1.000 0.446
CTCAE, Common Toxicity Criteria of Adverse Events of the National Cancer Institute (version 4.0); NA, not applicable. *P-values calculated by Fisher’s exact test.
Frontiers in Oncology | www.frontiersin.org 4 April 2019 | Volume 9 | Article 294
Okabe et al. Hochu-ekki-to to Reduce S-1 Toxicity
FIGURE 1 | Flow diagram of the 113 registered patients. Two patients treated with S-1 alone (group S) were diagnosed as T3N0, which did not meet the eligibility
criteria.
FIGURE 2 | Overall survival (A) and relapse-free survival (B) curves in patients treated with S-1 alone (group S) and S-1 plus TJ-41 (group ST).
was slightly higher in patients with S-1 plus TJ-41. Although
the difference was not significant, this was contrary to our
expectation that better completion rate would lead to better
survival. It was difficult to fully explain this unexpected result,
but higher proportion of T4 or N3 in patients with S-1 plus TJ-41
may be related to more frequent recurrence.
One limitation of this study is that the design was not
double-blinded. Because TJ-41 is an herbal medicine that has
a unique scent, developing a placebo is difficult and would
require considerable time and cost. We planned to conduct this
explorative phase II study first before conducting a double-blind
randomized controlled trial. Another limitation is that we did
not screen patients from the point of view of traditional Chinese
medicine. Because Chinese prescription is supposed to work
for patients in a certain status, selection of patients would be
necessary to evaluate its efficacy properly.
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FIGURE 3 | Odds ratios (ORs) for completion of S-1 adjuvant therapy and P-values for the interaction of treatment groups and clinical factors.
Current recommended adjuvant chemotherapy
regimens following gastrectomy differ somewhat among
countries. These regimens include S-1; capecitabine
and oxaliplatin (CapeOX); and epirubicin, oxaliplatin,
and oxaliplatin (EOX) (2, 4, 15). The efficacy of
each has been shown in clinical trials, but low
compliance rates are a common problem for these
regimens. Although this was a negative study, to find
new measures to increase compliance with current
regimens, as well as development of new agents to clear
residual cancer cells, would be an important strategy
to improve survival of patients after gastrectomy for
gastric cancer.
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